AR082408A1 - Derivados de pirimidina, composiciones y metodos para inhibicion de la via jak - Google Patents

Derivados de pirimidina, composiciones y metodos para inhibicion de la via jak

Info

Publication number
AR082408A1
AR082408A1 ARP110102733A ARP110102733A AR082408A1 AR 082408 A1 AR082408 A1 AR 082408A1 AR P110102733 A ARP110102733 A AR P110102733A AR P110102733 A ARP110102733 A AR P110102733A AR 082408 A1 AR082408 A1 AR 082408A1
Authority
AR
Argentina
Prior art keywords
alkyl
nra
ora
optionally substituted
membered
Prior art date
Application number
ARP110102733A
Other languages
English (en)
Spanish (es)
Inventor
Vanessa Taylor
Hui Li
Darren John Mmurtrie
Thilo Heckrodt
Sambaiah Thota
Pingyu Ding
Rose Yen
Yan Chen
Rajinder Singh
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of AR082408A1 publication Critical patent/AR082408A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ARP110102733A 2010-07-28 2011-07-28 Derivados de pirimidina, composiciones y metodos para inhibicion de la via jak AR082408A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36857010P 2010-07-28 2010-07-28

Publications (1)

Publication Number Publication Date
AR082408A1 true AR082408A1 (es) 2012-12-05

Family

ID=44504225

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110102733A AR082408A1 (es) 2010-07-28 2011-07-28 Derivados de pirimidina, composiciones y metodos para inhibicion de la via jak
ARP200102456A AR119882A2 (es) 2010-07-28 2020-09-02 Derivados de pirimidin-4-ilamino-benzooxazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200102456A AR119882A2 (es) 2010-07-28 2020-09-02 Derivados de pirimidin-4-ilamino-benzooxazol

Country Status (20)

Country Link
US (8) US8343954B2 (https=)
EP (1) EP2598500B1 (https=)
JP (2) JP6073221B2 (https=)
KR (1) KR101937495B1 (https=)
CN (1) CN103201280B (https=)
AR (2) AR082408A1 (https=)
AU (1) AU2011282742B2 (https=)
BR (1) BR112013001632B1 (https=)
CA (1) CA2804199C (https=)
DK (1) DK2598500T3 (https=)
EA (1) EA201390015A1 (https=)
ES (1) ES2880622T3 (https=)
IL (1) IL223855A (https=)
MX (2) MX347331B (https=)
PL (1) PL2598500T3 (https=)
PT (1) PT2598500T (https=)
RU (1) RU2672100C2 (https=)
TW (1) TWI582090B (https=)
WO (1) WO2012015972A1 (https=)
ZA (1) ZA201300388B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PL2565193T3 (pl) * 2009-01-23 2014-07-31 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
AU2011282742B2 (en) 2010-07-28 2015-08-27 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
ES2658395T3 (es) 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CA2899281C (en) * 2013-01-25 2022-05-31 Rigel Pharmaceuticals, Inc. Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
CA2904610A1 (en) * 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2016090079A1 (en) * 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
JP7167146B2 (ja) * 2017-11-06 2022-11-08 ブリストル-マイヤーズ スクイブ カンパニー Hpk1阻害剤として有用なイソフラノン化合物
US20210198248A1 (en) * 2018-05-24 2021-07-01 Astrazeneca Ab Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3h)-one
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110078633B (zh) * 2019-05-24 2021-05-11 爱斯特(成都)生物制药股份有限公司 一种4-氟-3-甲氧基-5-甲基苯胺盐酸盐制备方法
JP2023527242A (ja) * 2020-05-29 2023-06-27 南京正大天晴制薬有限公司 Axl阻害剤であるピリミジン系化合物
WO2025080099A1 (ko) * 2023-10-13 2025-04-17 주식회사유한양행 7,7-다이메틸푸로[3,4-b]피리딘-5(7h)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2025109026A1 (en) * 2023-11-21 2025-05-30 Intervet International B.V. Process for the preparation of 4-fluoro-3-methoxyaniline

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
UA96265C2 (ru) * 2005-06-08 2011-10-25 Райджел Фармасьютикалс, Инк. Композиция и способ ингибирования jak пути передачи сигнала
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8393954B2 (en) 2006-12-29 2013-03-12 Cfph, Llc Top performers
US8456526B2 (en) * 2006-08-25 2013-06-04 Sportvision, Inc. Video effect using movement within an image
US7947698B2 (en) * 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2009063240A1 (en) * 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
PL2565193T3 (pl) * 2009-01-23 2014-07-31 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
AU2011282742B2 (en) * 2010-07-28 2015-08-27 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8637038B2 (en) * 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection

Also Published As

Publication number Publication date
US20130090310A1 (en) 2013-04-11
US20180162848A1 (en) 2018-06-14
US20150259332A1 (en) 2015-09-17
ES2880622T3 (es) 2021-11-25
CN103201280B (zh) 2016-08-10
KR101937495B1 (ko) 2019-01-10
US9611260B2 (en) 2017-04-04
JP6073221B2 (ja) 2017-02-01
EA201390015A1 (ru) 2013-07-30
CA2804199C (en) 2020-05-12
EP2598500B1 (en) 2021-05-19
DK2598500T3 (da) 2021-07-26
US20220024907A1 (en) 2022-01-27
RU2672100C2 (ru) 2018-11-12
PL2598500T3 (pl) 2021-11-29
WO2012015972A1 (en) 2012-02-02
US20120028923A1 (en) 2012-02-02
JP2017061518A (ja) 2017-03-30
BR112013001632B1 (pt) 2021-05-25
US20200115371A1 (en) 2020-04-16
US10479783B2 (en) 2019-11-19
AU2011282742B2 (en) 2015-08-27
US20170158683A1 (en) 2017-06-08
JP2013536179A (ja) 2013-09-19
AU2011282742A1 (en) 2013-02-07
IL223855A (en) 2016-05-31
US11174251B2 (en) 2021-11-16
BR112013001632A2 (pt) 2016-05-24
TWI582090B (zh) 2017-05-11
US9920041B2 (en) 2018-03-20
CA2804199A1 (en) 2012-02-02
ZA201300388B (en) 2013-09-25
US9067925B2 (en) 2015-06-30
RU2015122016A (ru) 2016-12-27
MX2020009397A (es) 2020-12-03
CN103201280A (zh) 2013-07-10
US8343954B2 (en) 2013-01-01
MX2013000757A (es) 2013-04-29
MX347331B (es) 2017-04-21
PT2598500T (pt) 2021-07-22
AU2011282742A2 (en) 2013-04-04
USRE47396E1 (en) 2019-05-21
KR20130132406A (ko) 2013-12-04
AR119882A2 (es) 2022-01-19
TW201209053A (en) 2012-03-01
EP2598500A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
AR082408A1 (es) Derivados de pirimidina, composiciones y metodos para inhibicion de la via jak
EA201100620A1 (ru) Способ получения 2-алкил-3-ароил-5-нитробензофуранов
AR072845A1 (es) 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas.
AR076620A1 (es) 2,4 DIAMINOPIRIMIDINAS, COMPOSICIONES FARMACEUTICAS, PROCESOS DE PREPARACIoN Y SU USO COMO MEDICAMENTO.
RU2013147400A (ru) Способ получения производных кето-бензофурана
AR070728A1 (es) Derivados de pirazolo[1,5-a]pirimidina, composicion farmaceutica que los comprende y metodo para hacer el compuesto, asociable con la inhibicion de la actividad raf quinasa en un mamifero
EA201071112A1 (ru) ПРОИЗВОДНЫЕ ПОЛИЗАМЕЩЁННЫХ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ИХ В ТЕРАПИИ
AR086191A1 (es) Triazolopiridinas
AR076134A1 (es) Derivados de 2,4 diaminopirimidinas
AR057423A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento
EP4329431A3 (en) Novel heteroleptic iridium complexes
ES2432821T3 (es) Compuestos de pirimidina, composiciones y métodos de utilización
AR071673A1 (es) Procedimiento para la preparacion de compuestos pirazolicos sustituidos en posiciones 1,3,4
RU2014140735A (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201070895A1 (ru) Карбамидные производные тетрагидрохиноксалина, их получение и их применение в терапии
NO20091451L (no) Bicykliske heteroaromatiske forbindelser
CY1114748T1 (el) Ενωσεις που εχουν δραστικοτητα crth2 ανταγωνιστη
AR081814A1 (es) Modificador del sabor dulce
EA201100932A1 (ru) Соединения пуриновых нуклеозидов и способ их получения
JP2012511588A5 (https=)
CO6150038A1 (es) Nuevos derivados de diosmetina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
MX2017015496A (es) Fosforilacion selectiva sin disolvente.
RU2012116525A (ru) Способы получения перемидиновых производных, пригодных в качестве ингибиторов протеинкиназ
AR051743A1 (es) Tiazolil - dihidro- indazoles
RU2014143794A (ru) Производное конденсированного азола

Legal Events

Date Code Title Description
FG Grant, registration